Assessment of epicutaneous testing of a monovalent Influenza A (H1N1) 2009 vaccine in egg allergic patients
<p>Abstract</p> <p>Background</p> <p>H1N1 is responsible for the first influenza pandemic in 41 years. In the fall of 2009, an H1N1 vaccine became available in Canada with the hopes of reducing the overall effect of the pandemic. The purpose of this study was to assess...
Main Authors: | Pitt Tracy, Kalicinsky Chrystyna, Warrington Richard, Cisneros Nestor |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-02-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Online Access: | http://www.aacijournal.com/content/7/1/3 |
Similar Items
-
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
by: Clark, Tristan, et al.
Published: (2009) -
An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11
by: Lee Esther ST, et al.
Published: (2011-08-01) -
Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients.
by: João L Miraglia, et al.
Published: (2011-01-01) -
CLINICAL TRIAL OF THE PANDEMIC INFLUENZA MONOVALENT VACCINE PANDEFLU
by: M. K. Erofeeva, et al.
Published: (2014-07-01) -
Recommendations for the administration of influenza vaccine in children allergic to egg
by: Erlewyn-Lajeunesse, M., et al.
Published: (2009)